The company's monitoring platform utilizes low-pass whole-genome sequencing and DNA methylation analysis to provide oncologists with clinically actionable information about cancer diagnosis, treatment, and response to therapy. This technology is faster and more accurate than imaging, allowing for earlier detection of patient response to treatment. Lexent Bio's liquid biopsy technology has the potential to change the way we diagnose and treat cancer.